Retinoids for the treatment of psoriasis: Outlook for the future

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 625-630

  Kuenzli, S ^a   Saurat, J H ^a  

^a University Hospital   (Switzerland)

Author keywords

Acitretin; Psoriasis; Retinoids; Tazarotene; UV

Indexed keywords

ADAPALENE; ANTIPSORIASIS AGENT; CORTICOSTEROID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOSPORIN; DITHRANOL; ETRETIN; ETRETINATE; FLUOCINONIDE; ISOTRETINOIN; LIGAND; METHOTREXATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOID X RECEPTOR; TAZAROTENE; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TROGLITAZONE; VITAMIN D RECEPTOR;

ALCOHOL CONSUMPTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DISSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG USE; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KERATINOCYTE; LIVER TOXICITY; MOLECULAR INTERACTION; MONOTHERAPY; PANCREATITIS; PREGNANCY; PSORIASIS; PUSTULAR PSORIASIS; PUVA; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; SKIN DISEASE; TERATOGENICITY; TREATMENT OUTCOME;

ANIMALS; HUMANS; PSORIASIS; RETINOIDS; ULTRAVIOLET THERAPY;

EID: 0034980609     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment
2. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: Detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161
3. Metabolism of natural retinoids in psoriatic epidermis
4. Overexpression of cellular retinoic acid-binding protein type II (CRABP2) and down-regulation of CRABP1 in psoriatic skin
5. Systemic retinoids. What's new?
6. Acitretin and etretinate
7. Tazarotene-first of a new generation of receptor-selective retinoids
8. New retinoids with potential use in humans
9. Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin)
10. Pharmacokinetics of acitretin and etretinate
11. Pharmacokinetics of acitretin in humans
12. Acitretin is converted to etretinate only during concomitant alcohol intake
13. Acitretin and etretinate in the treatment of palmoplantar pustulosis: A double-blind comparative trial
14. Acitretin (Ro 10-1670) in the treatment of severe prosiasis: A randomized double-blind parallel study comparing acitretin and etretinate (Tigason)
15. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study
16. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study
17. Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients
18. Acitretin (Ro 10-1670, etretin): Overall evaluation of clinical studies
19. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis
20. Etretinate in pustular psoriasis of palms and soles
21. Etretinate in severe psoriasis
22. Etretinate therapy in generalized pustular psoriasis (Zumbusch type)
23. Maintenance treatment of psoriasis by Tigason: A double-blind randomized clinical trial
24. International studies of the efficacy of etretinate in the treatment of psoriasis
25. Etretinate therapy
26. Etretin therapy for severe psoriasis
27. When systemic retinoids fail to work in psoriasis
28. Efficacy of acitretin in severe cutaneous lichen planus
29. Etretinate (Tigason, Europe; Tegison, USA) in psoriasis: Advantages of low doses progressively increased
30. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis
31. Treatment of severe psoriasis with etretin (Ro 10-1670)
32. Acitretin improves psoriasis in a dose-dependent fashion
33. Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: A double-blind trial
34. Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis
35. Treatment of psoriasis by oral PUVA therapy combined with aromatic retinoid (Ro 10-9359; Tigason)
36. Therapy of psoriasis with retinoid plus PUVA: Clinical and histologic data
37. A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA and PUVA alone in severe psoriasis
38. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative
39. Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study
40. PUVA and cancer: A large-scale epidemiological study
41. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis
42. Oral retinoid and UVB radiation: A new alternative treatment for psoriasis on an outpatient basis
43. Acitretin plus UVB therapy for psoriasis
44. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis
45. Teratogenesis and reproductive safety evaluation of the retinoid etretin (Ro 10-1670)
46. Acitretin in psoriasis: An overview of adverse effects
47. Risk: Benefit ratio in the treatment of psoriasis with systemic retinoids
48. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis
49. Isotretinoin-PUVA for psoriasis
50. Isotretinoin-PUVA in women with psoriasis
51. Treatment of female patients with isotretinoin: What is the safe post-therapy contraceptive period?
52. Clinical pharmacokinetics and drug metabolism of tazarotene: A novel topical treatment for acne and psoriasis
53. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne
54. Optimising the use of tazarotene in clinical practice: Consensus statement from the European Advisory Panel for tazarotene (Zorac™)
55. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect
56. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis
57. Tazarotene combination treatments in psoriasis
58. Tazarotene plus UVB phototherapy in the treatment of psoriasis
59. Tazarotene in combination with phototherapy
60. Future trends: A new generation of retinoids
61. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha
62. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
63. Regulation of Gli activity by all-trans retinoic acid in mouse keratinocytes
64. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma
65. Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis
66. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation